Stock REPROS THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Repros Therapeutics Inc Stock

Equities

US76028H2094

Biotechnology & Medical Research

Chart Repros Therapeutics Inc

Dynamic Chart

Press releases Repros Therapeutics Inc

Repros Announces Negative Opinion From the EMA for Enclomiphene GL
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency GL
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc GL
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results GL
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results GL
More press releases

News in other languages on Repros Therapeutics Inc

Apple : Les valeurs à suivre sur les marchés américains
More news

Managers and Directors - Repros Therapeutics Inc

Managers TitleAgeSince
Ambrose Bailey PSD
 President 60 18-01-30
Joachim F. Wernicke CTO
 Chief Tech/Sci/R&D Officer 76 13-02-04
Kira Schwartz SEC
 Corporate Secretary - 18-01-30
More insiders

Company Profile

More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+41.53% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. Stock